News | Heart Valve Technology | November 08, 2017

New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients

Presented at TCT, Evolut TAVR platform showcases positive clinical outcomes in patients wanting to return to more active lives

New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients

November 8, 2017 —  Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut Transcatheter Aortic Valve Replacement (TAVR) Platform in intermediate-risk, severe, symptomatic, aortic stenosis patients. Outcomes from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial and the Evolut R FORWARD “real-world” study were presented at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting, Oct. 29-Nov. 2, in Denver, reinforcing the valve’s strong performance in healthier, more active patients.

Complete one-year outcomes from the SURTAVI trial based on Kaplan-Meier analyses confirmed the strong performance of the CoreValve and Evolut R TAVR systems versus the gold standard of open-heart surgery in an intermediate-risk severe symptomatic aortic stenosis patient population. The results indicate the platform continued to provide comparable results to surgery with regard to the primary combined endpoint of all-cause mortality or disabling stroke (7.8 percent for TAVR vs. 8.5 percent for surgery; p=0.55) at one year. A subgroup analysis of the SURTAVI Continued Access Study (CAS) showed consistently positive safety data for the Evolut R System in intermediate-risk patients with high rates of survival (100 percent) and low rates of all stroke (1.5 percent) or disabling stroke (0.4 percent) at 30-days.

“With its supra-annular and self-expanding design, the Evolut TAVR platform is well-suited to deliver excellent valve performance for intermediate-risk patients who are often considered to be more active than high- or extreme-risk patients,” said Nicolas M. Van Mieghem, M.D., director of interventional cardiology at Erasmus Medical Center in Rotterdam, the Netherlands, and presenter of the SURTAVI one-year data at the meeting. “As new clinical data are gathered for this patient population, we continue to see the exceptional clinical benefits this self-expanding valve provides as a minimally-invasive treatment alternative to surgery.”

Additionally, a sub-analysis from the SURTAVI trial where patients were stratified based on their STS Predicted Risk of Mortality (PROM) showed that TAVR patients demonstrated a significantly lower rate of all-cause mortality or disabling stroke at one year (1.5 percent vs. 6.5 percent; p=0.04) in the category of patients with STS-PROM < 3 percent. Patients treated with TAVR also showed mortality improvements across risk categories at one year, whereas surgical mortality rates were similar across all STS score categories.

Similarly, results from a subset of 257 “real-world” patients enrolled in the Evolut R FORWARD Study with an STS PROM < 3 percent demonstrated excellent clinical outcomes, with a low rate of all-cause mortality (2 percent) and disabling stroke (1.2 percent) at 30-days post implant.

The CoreValve Evolut TAVR platform consists of the CoreValve, CoreValve Evolut R and the Evolut PRO systems, which are available for use in the United States and Europe for severe aortic stenosis patients at an intermediate surgical risk or greater.

Watch the VIDEO "TAVR Stands Equal to Surgical Valve Replacement" — an interview with Michael Reardon, M.D.

 

 

Related Content

TCT 2017 Late-breaking Clinical Trial Presentations

 

References:

1. Michael J. Reardon, M.D., Nicolas M. Van Mieghem, M.D., Ph.D., Jeffrey J. Popma, et al. “Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients.” N Engl J Med 2017; 376:1321-1331April 6, 2017DOI: 10.1056/NEJMoa1700456. 

2. Eberhard Grube, Nicolas M. Van Mieghem, Sabine Bleiziffer, et al. “Clinical Outcomes With a Repositionable Self-Expanding Transcatheter Aortic Valve Prosthesis: The International FORWARD Study.” JACC. Volume 70, Issue 7, August 2017. DOI: 10.1016/j.jacc.2017.06.045

 

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init